The incidence of breast cancer is increasing year by year, but the results are better compared to other organ malignancies, as shown by the good quality of life of patients, high overall survival rate, 5-year and 10-year disease-free survival rate, and active treatment measures even for recurrence and metastasis, but these are based on standardized and comprehensive treatment: including surgery, chemotherapy, radiotherapy, endocrine therapy, etc. The necessary surgery, chemotherapy, radiotherapy and other methods are After half a year, estrogen receptor (ER) and estrogen receptor (PR) positive patients need up to 5 years of endocrine therapy, during which patients often feel good about themselves and some of them have gone to work, plus endocrine therapy has more or less side effects, and some patients cannot adhere to the medication and stop on their own. This is what doctors hate to see, and it is also irresponsible behavior of patients to themselves. The development of breast cancer may be directly related to estrone and estradiol in the patient’s body, and endocrine therapy is aimed at patients who are estrogen receptor (ER) and estrogen receptor (PR) positive. . How does a doctor choose the right endocrine therapy for a specific patient? The first step is to correctly determine whether the patient is pre-menopausal or post-menopausal? Menopause does not simply mean the cessation of menstruation or amenorrhea, it has strict rules. The following conditions are defined as postmenopausal, otherwise premenopausal: 1. Bilateral ovarian resection; 2. Age > 60 years; 3. Age < 60 years, the following points need to be met: amenorrhea > 12 months, no chemotherapy, triamcinolone, toremifene or ovarian suppression, and follicle stimulating hormone and estrogen in the postmenopausal range. 4. Age < 60 years who have received triamcinolone or toremifene, then follicle stimulating hormone and serum estrogen levels in the postmenopausal range are required. Premenopausal adjuvant endocrine therapy options 1. triamcinolone acetonide or phalloidin for 5 years 2.Triamcinolone or phalloctone, 2-3 years of treatment, if entering postmenopause can be switched to treatment with aromatase inhibitors (including letrozole, anastrozole, exemestane) for a total of 5 years, if triamcinolone treatment for 5 years before entering postmenopause, switch to follow-up intensive treatment with letrozole, anastrozole or exemestane for 2-5 years, letrozole is available domestically and imported. 3.Young patients with high-risk recurrence factors (such as poorly differentiated tumors, lymph node metastasis, vascular tumor emboli, etc.) can be considered for ovarian function inhibition (laparoscopic bilateral ovaries or using Norelide, subcutaneous injection, every 28 days) after choosing triamcinolone acetonide (TAM) or aromatase inhibitors (including letrozole, anastrozole, exemestane treatment. 4. For some people who are not suitable for triamcinolone therapy, aromatase inhibitor therapy can be considered after effective ovarian function suppression. Postmenopausal adjuvant endocrine therapy options 1. Prefer aromatase inhibitors (including letrozole, anastrozole, exemestane) for 5 years. 2. Treatment with aromatase inhibitors (including letrozole, anastrozole, exemestane) for 2-3 years first, then switch to triamcinolone for 2-3 years. 3.If the economic situation does not allow, or cannot tolerate the side effects of aromatase inhibitors, you can also take triamcinolone acetonide directly for 5 years. 4.Patients who are now taking triamcinolone therapy can change to aromatase inhibitors at any time. The above, for reference only, specific patients can consult with the competent doctor to decide the selection of drugs, do not arbitrarily stop the drug on their own.